Dosimetry
- Dosimetry is the accountant of nuclear medicine: it estimates how much radiation energy a given organ actually soaks up from a radiopharmaceutical.
- The headline unit is the gray (Gy) — energy absorbed per unit mass (joules per kilogram). It measures deposited dose, not the activity you injected.
- Absorbed dose depends on three things: how much tracer lands in the tissue, how long it lingers there, and the kind of radiation it emits.
- It matters most for therapy (Lu-177, I-131, Y-90), where we're deliberately trying to fry tumor while sparing kidneys, marrow, and salivary glands.
- Diagnostic scans deliver tiny doses; therapy doses are orders of magnitude larger, which is exactly why someone has to do the math.
Here's the uncomfortable truth about theranostics: when you inject a patient with a radioactive drug designed to kill cells, you'd really like to know how much radiation each organ is getting. Not "roughly a lot." A number. That number-hunting is dosimetry, and it's basically forensic accounting for radiation — following the energy around the body and tallying who got what.
What we're actually measuring
The unit at the center of everything is the gray (Gy): one joule of energy absorbed per kilogram of tissue. That's it. Dosimetry is the art of figuring out the gray.
The crucial mental shift is this: the dose to a tumor is not the dose you injected. You inject activity (measured in becquerels or curies) — that's how many atoms are decaying per second. But the gray is about energy absorbed by tissue. A tracer that flies straight out in the urine deposits almost nothing; a tracer that parks itself in a tumor for days deposits a lot. Same injected activity, wildly different absorbed dose.
Think of it like rainfall versus a flooded basement. Activity is how hard it's raining. Absorbed dose is how much water ends up in your particular basement — which depends on where the rain falls and how long it pools before draining.
Dose and activity are different questions and use different units. Activity (Bq, Ci) = decays per second, what you draw up in the syringe. Absorbed dose (Gy) = energy deposited per kilogram, what the tissue actually experiences. Don't let anyone hand you a becquerel and call it a dose.
The three things that set the dose
Strip away the equations and dosimetry comes down to a simple shopping list for each organ:
- How much tracer arrives — the fraction of injected activity that ends up in that tissue (the "uptake").
- How long it stays — governed by both physical decay and the body washing it out. Together these give the effective half-life, which is always shorter than the physical half-life because biology helps clean house.
- What kind of radiation comes out — and this is where it gets interesting.
That third point is the whole reason some isotopes are for pictures and others are for therapy.
Why beta and alpha particles do the killing
Gamma rays (and the high-energy photons a positron makes when it annihilates) are great for imaging because they zip out of the body to a camera. But for therapy, escaping energy is wasted energy. You want radiation that stops dead in the tissue and dumps every bit of its punch locally.
- Beta emitters (Lu-177, Y-90, I-131) shed electrons that travel a few millimeters before stopping — perfect for depositing energy right where the tracer sits.
- Alpha emitters (like Ra-223) hit even harder over a much shorter range — a few cell-widths — making them devastating but exquisitely local.
Picture a shotgun versus a sniper rifle versus a flashlight. The gamma ray is the flashlight, lighting up the room (and the camera) but barely warming anything. Beta is the shotgun — short range, lots of local damage. Alpha is the sniper round at point-blank: tiny footprint, enormous local energy.
The same molecule with a different radioactive label can be a camera or a weapon. Swap a gamma/positron emitter for a beta or alpha emitter and the "see it" agent becomes the "treat it" agent — that's the core trick of theranostics, and dosimetry is how you dose it safely.
How the number actually gets made
You can't measure absorbed dose directly inside a living organ, so dosimetry estimates it. The standard recipe — the framework most centers use is the MIRD approach — goes like this:
- Image the patient at several time points after the therapy dose (or a small "tracer" pre-dose) to see where the activity goes and how fast it leaves.
- Draw the curve of activity-over-time for each organ, and find the area under that curve — the total number of decays that happened in that tissue.
- Multiply by how much energy each decay deposits locally, accounting for organ size.
The output is grays to the tumor (you want this high) and grays to the organs at risk — for Lu-177 therapies that's usually the kidneys and bone marrow; for I-131 it's marrow and the salivary glands. The whole game is maximizing tumor dose while keeping those bystanders under their tolerance.
A long physical half-life does not mean a long effective half-life. A tracer that the kidneys flush out quickly can deliver far less dose than its isotope's half-life suggests. Always reason from effective half-life — physical decay and biological clearance both count, and biology often wins.
Diagnostic versus therapeutic: two different universes
For a routine diagnostic scan, the absorbed doses are small and we mostly care about long-term stochastic risk — the statistical bump in lifetime cancer odds, covered under deterministic vs stochastic effects. Nobody's calculating per-organ grays for a standard FDG-PET; the dose is too low to bother.
Therapy is the opposite universe. The doses are large enough to cause real, deterministic organ damage if you're careless — which is precisely why someone sits down and does the dosimetry. The difference in scale is the difference between a single raindrop and the flooded basement.
Dosimetry units (gray) measure absorbed dose — physical energy. That's distinct from the effective dose in sieverts (Sv) used to compare whole-body radiation risk across modalities, explained over in radiation units and quantities. Same family, different jobs: gray asks "how much energy here?"; sievert asks "how much risk overall?"
The one thing to remember
Dosimetry exists because activity injected is not dose delivered. Where the tracer goes, how long it stays, and what kind of radiation it spits out together decide which organ pays the bill — and in the therapy world, getting that bill right is the difference between treating the cancer and harming the patient.